BioStem Technologies, Inc.
NNASDAQ:BSEM1.66
USD
-0.02
(-1.19%)
CIK
1658678
ISIN
US0906842002
CUSIP
090684200
Return %
Stock
S&P 500
1Y
-66.05
14.20
3Y
-55.26
81.12
5Y
15.28
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jason Matuszewski
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Pompano Beach United States
- IPO Date
- Jul 11, 2001
- CIK
- 0001658678
- Website
- biostemtechnologies.com
- Similar Companies
- Business
- BioStem Technologies, Inc. is a commercial-stage regenerative medicine and biotechnology company that discovers, develops, manufactures, and commercializes perinatal tissue-derived allografts for advanced wound care, surgical reconstruction, and regenerative therapies. The company utilizes proprietary, patented tissue-processing platforms, including its BioREtain preservation process, CryoTek cryopreservation method, and SteriTek sterilization technology, to retain the native structural extracellular matrix, bioactive growth factors, and anti-inflammatory cytokines found in human placental tissues. BioStem Technologies offers a diversified portfolio of specialized biologic products, which comprises VENDAJE, a dehydrated human amniotic membrane allograft indicated as a protective barrier and tissue scaffold for acute and chronic wounds; VENDAJE AC, a multi-layer dehydrated amnion-chorion structural allograft engineered for complex soft tissue defects, diabetic foot ulcers, and venous leg ulcers; NEOX, a cryopreserved umbilical cord and amniotic membrane matrix utilized in surgical and deep wound repair; and CLARIX, a cryopreserved amniotic membrane allograft engineered to modulate inflammation, minimize scar tissue formation, and support surgical soft tissue reconstruction. The company distributes its products across hospital operating rooms, ambulatory surgical centers, outpatient wound care facilities, and physician offices throughout the United States through a nationwide direct sales force and established group purchasing organization contracts. In recent developments, BioStem Technologies completed the strategic acquisition of the non-ocular surgical and wound care business of BioTissue Holdings, Inc., expanding its product offering with the NEOX and CLARIX brands and accelerating its commercial expansion into hospital operating environments. The company has also advanced its clinical research programs with randomized controlled trials evaluating wound healing efficacy, strengthened its national reimbursement and distribution channels, and advanced the uplisting of its common stock to the Nasdaq Capital Market under the ticker symbol BSEM. BioStem Technologies, Inc. was incorporated in 2009 and is headquartered in Pompano Beach, Florida.